<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article12</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/OASIS-5" style="display:block; margin-bottom:10px;">OASIS-5 Original</a></li>
<h2><strong>OASIS-5</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
The New England Journal of Medicine. 2006. 354(14):1464-1476.<br/>
PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1. Clinical Question<br/>
2. Bottom Line<br/>
3. Major Points<br/>
4. Guidelines<br/>
5. Design<br/>
6. Population<br/>
    6.1 Inclusion Criteria<br/>
    6.2 Exclusion Criteria<br/>
    6.3 Baseline Characteristics<br/>
7. Interventions<br/>
8. Outcomes<br/>
    8.1 Primary Outcome<br/>
    8.2 Secondary Outcomes<br/>
9. Criticisms<br/>
10. Funding<br/>
11. Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
In patients with acute coronary syndromes, does fondaparinux, compared to enoxaparin, reduce ischemic events without increasing bleeding?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
Fondaparinux was noninferior to enoxaparin in preventing ischemic events in acute coronary syndromes, significantly reduced major bleeding, and improved long-term mortality and morbidity.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/>
Fondaparinux, a synthetic pentasaccharide, potentially offers a better bleeding profile than enoxaparin while providing comparable anticoagulant effects for ischemic event reduction in acute coronary syndromes.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/>
Recommendations for the use of fondaparinux may be influenced by these findings; however, specific guidelines resulting from this trial could vary by organization.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Multicenter, double-blind, randomized controlled trial<br/>
- N=20,078 patients with acute coronary syndromes<br/>
- Fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kg twice daily)<br/>
- Mean follow-up: 6 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
- Inclusion Criteria: Patients with acute coronary syndromes, specifically unstable angina or myocardial infarction without ST-segment elevation, within 24 hours of symptom onset<br/>
- Exclusion Criteria: Contraindications to low-molecular-weight heparin, recent hemorrhagic stroke, other indications for anticoagulation, serum creatinine ≥3 mg/dL<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Fondaparinux 2.5 mg subcutaneously once daily plus placebo enoxaparin<br/>
- Enoxaparin 1 mg per kg subcutaneously twice daily plus placebo fondaparinux<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
- Primary Outcome: Death, myocardial infarction, or refractory ischemia at nine days; major bleeding events<br/>
- Secondary Outcomes: Death, myocardial infarction, refractory ischemia, strokes at 30 days and at 180 days, major bleeding events throughout the study<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
<br/>
- The study design and patient selection could potentially impact the generalizability of the trial results to broader acute coronary syndrome populations.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
The trial was supported by Sanofi-Aventis, Organon, and GlaxoSmithKline. Disclosure of potential conflicts of interest by the trial's authors included receipt of consulting fees, lecture fees, and research grants from the pharmaceutical companies supporting the trial.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
Additional readings include publications in cardiovascular medical journals discussing the impact of bleeding on acute coronary syndrome outcomes and the usage of fondaparinux in clinical practice.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
